Empagliflozin had the potential to ameliorate MI-induced myocardial fibrosis by inhibiting the expression of miR-181a, suppressing the TGF-β1/Smad3 signaling pathways in the myocardial tissue [221]. The gene discussed is TGFB1; the disease is Myocardial fibrosis.